JP Morgan Chase’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-820,990
| Closed | -$59.2M | – | 7836 |
|
|
2025
Q4 | $59.2M | Sell |
820,990
-78,567
| -9% | -$5.07M | ﹤0.01% | 1252 |
|
|
2025
Q3 | $39.2M | Buy |
899,557
+319,282
| +55% | +$12.9M | ﹤0.01% | 1571 |
|
|
2025
Q2 | $16.5M | Buy |
580,275
+139,473
| +32% | +$4.16M | ﹤0.01% | 2106 |
|
|
2025
Q1 | $13M | Sell |
440,802
-9,342
| -2% | -$291K | ﹤0.01% | 2307 |
|
|
2024
Q4 | $13.1M | Sell |
450,144
-16,941
| -4% | -$708K | ﹤0.01% | 2445 |
|
|
2024
Q3 | $21.5M | Sell |
467,085
-14,395
| -3% | -$625K | ﹤0.01% | 1932 |
|
|
2024
Q2 | $19.7M | Sell |
481,480
-411,994
| -46% | -$11.8M | ﹤0.01% | 1885 |
|
|
2024
Q1 | $22.8M | Sell |
893,474
-74,429
| -8% | -$1.17M | ﹤0.01% | 1791 |
|
|
2023
Q4 | $8.76M | Sell |
967,903
-2,799
| -0.3% | -$18.7K | ﹤0.01% | 2602 |
|
|
2023
Q3 | $6.19M | Buy |
970,702
+420,695
| +76% | +$3.62M | ﹤0.01% | 2673 |
|
|
2023
Q2 | $6.1M | Sell |
550,007
-2,977
| -0.5% | -$37.3K | ﹤0.01% | 2704 |
|
|
2023
Q1 | $8.49M | Buy |
552,984
+428,066
| +343% | +$9.42M | ﹤0.01% | 2417 |
|
|
2022
Q4 | $2.77M | Buy |
124,918
+13,797
| +12% | +$206K | ﹤0.01% | 3310 |
|
|
2022
Q3 | $1.81M | Sell |
111,121
-15,461
| -12% | -$296K | ﹤0.01% | 3558 |
|
|
2022
Q2 | $1.84M | Buy |
126,582
+25,467
| +25% | +$379K | ﹤0.01% | 3616 |
|
|
2022
Q1 | $1.87M | Sell |
101,115
-10,256
| -9% | -$174K | ﹤0.01% | 3817 |
|
|
2021
Q4 | $2.65M | Buy |
111,371
+84,266
| +311% | +$2.01M | ﹤0.01% | 3626 |
|
|
2021
Q3 | $668K | Buy |
27,105
+9,827
| +57% | +$214K | ﹤0.01% | 4560 |
|
|
2021
Q2 | $427K | Buy |
17,278
+2,139
| +14% | +$49.8K | ﹤0.01% | 4789 |
|
|
2021
Q1 | $330K | Buy |
15,139
+7,630
| +102% | +$187K | ﹤0.01% | 4917 |
|
|
2020
Q4 | $192K | Buy |
7,509
+1,274
| +20% | +$37.2K | ﹤0.01% | 4819 |
|
|
2020
Q3 | $180K | Buy |
+6,235
| New | +$180K | ﹤0.01% | 4413 |
|
Other funds holding RNAM
JP Morgan Chase's RNAM Position: Q1 2026 in Review
JP Morgan Chase sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 820,990 shares — an estimated $59.2M sold.
JP Morgan Chase first reported a position in RNAM in Q3 2020 and held it in 22 quarters. The position peaked at $59.2M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- JP Morgan Chase reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- JP Morgan Chase sold 820,990 Avidity Biosciences shares in Q1 2026, an estimated $59.2M.
- JP Morgan Chase first reported a position in Avidity Biosciences in Q3 2020 and held it in 22 quarters.
- JP Morgan Chase's Avidity Biosciences position peaked at $59.2M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.